Delving into the Latest Updates on HT006.2.2 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

HT006.2.2

Target

TrkA x p75NTR

Action

activators, agonists

Mechanism

TrkA activators(Nerve growth factor receptor Trk-A activators), p75NTR agonists(Low affinity neurotrophin receptor p75NTR agonists)

Therapeutic Areas

Eye DiseasesOther Diseases

Active Indication

Neurotrophic keratitis

Inactive Indication-

Originator Organization

Wuhan Hiteck Biological Pharma Co., Ltd.

Active Organization

Wuhan Hiteck Biological Pharma Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

评价在中国健康受试者中单次、多次局部给予 rhNGF 滴眼液后的局部（眼部）和全身系统安全性、耐受性。评价在中国健康受试者中单次、多次局部给予 rhNGF 滴眼液后的全身系统药代动力学特征。评价在中国健康受试者中单次、多次局部给予 rhNGF 滴眼液后的全身系统免疫原性。评价 rhNGF 滴眼液在中国健康受试者眼内单次给药后的局部药代动力学特征。

[Translation]

To evaluate the local (ocular) and systemic safety and tolerability of rhNGF eye drops after single and multiple topical administrations in healthy Chinese subjects. To evaluate the systemic pharmacokinetic characteristics of rhNGF eye drops after single and multiple topical administrations in healthy Chinese subjects. To evaluate the systemic immunogenicity of rhNGF eye drops after single and multiple topical administrations in healthy Chinese subjects. To evaluate the local pharmacokinetic characteristics of rhNGF eye drops after a single intraocular administration in healthy Chinese subjects.

Start Date-

Sponsor / Collaborator

Wuhan Hiteck Biological Pharma Co., Ltd.

100 Clinical Results associated with HT006.2.2

Login to view more data

100 Translational Medicine associated with HT006.2.2

Login to view more data

100 Patents (Medical) associated with HT006.2.2

Login to view more data

100 Deals associated with HT006.2.2

Login to view more data